Is Flow Cytometric Immunophenotyping Useful for Predicting Acute Myeloid Leukemia Prognosis?

2017 ◽  
Vol 18 (4) ◽  
pp. 200-204
Author(s):  
Hava Usküdar Teke ◽  
Nur Oguz Davutoglu ◽  
Eren Gunduz ◽  
Neslihan Andic ◽  
Cengiz Bal ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Flow Cytometric Immunophenotyping ◽  
Flow Cytometric ◽  
Acute Myeloid

The Value of CD64 Expression in Distinguishing Acute Myeloid Leukemia With Monocytic Differentiation From Other Subtypes of Acute Myeloid Leukemia: A Flow Cytometric Analysis of 64 Cases

2007 ◽  
Vol 131 (5) ◽  
pp. 748-754
Author(s):  
Cherie H. Dunphy ◽  
Wohzan Tang
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Flow Cytometric Analysis ◽  
World Health ◽  
Monocytic Differentiation ◽  
Flow Cytometric Immunophenotyping ◽  
Cd64 Expression ◽  
Flow Cytometric ◽  
Health Organization ◽  
Acute Myeloid

Abstract Context.—Flow cytometric immunophenotyping is a useful ancillary tool in the diagnosis and subclassification of acute myeloid leukemias (AMLs). A recent study concluded that CD64 is sensitive and specific for distinguishing AMLs with a monocytic component (ie, AML M4 and AML M5) from other AML subtypes. However, in that study, the intensity of CD64 was not well defined and the number of non-M4/non-M5 AMLs was small. Objective.—To evaluate the usefulness of CD64 by flow cytometric immunophenotyping in distinguishing AMLs with monocytic differentiation from other AML subtypes. Design.—Sixty-four AMLs subclassified based on the French-American-British and World Health Organization classifications on pretreatment bone marrows were retrieved from our files (7 M0s, 11 M1s, 17 M2s, 7 M3s, 9 M4s, 7 M5s, 4 M6s, and 2 M7s). A standard panel of markers, including CD2, CD3, CD5, CD7, CD10, CD11b, CD13, CD14, CD15, CD19, CD20, CD33, CD34, CD45, CD56, CD64, CD117, and HLA-DR, were analyzed by flow cytometric immunophenotyping in all AMLs (52 bone marrow samples; 12 peripheral blood samples). Results.—CD64 was expressed in AML subtypes M0 to M5 in varying intensities: heterogeneously expressed in 1 of 7 M0s; dimly expressed in 3 of 11 M1s; dimly and moderately expressed in 6 and 2 of 17 M2s, respectively; dimly and moderately expressed in 5 and 1 of 7 M3s, respectively; dimly expressed in 4 of 9 M4s; and heterogeneously, moderately, and strongly expressed in 1, 3, and 3 of 7 M5s, respectively. Conclusions.—Strong CD64 expression distinguishes AML M5; however, heterogeneous, dim, or moderate expression in itself does not distinguish M0 through M4 subtypes from M5 with dim to moderate CD64 expression. However, any CD64 expression associated with strong CD15 expression distinguishes AML M4 or M5, from other AML subtypes.

scholarly journals Quantifying the loss of ABO antigenicity in a patient with acute myeloid leukemia by flow cytometric analysis

2020 ◽  
Vol 11 (1) ◽  
pp. 5-7
Author(s):  
Hazel J. Popp ◽  
Margaret Nelson ◽  
Cecily Forsyth ◽  
Mark Falson ◽  
Harry Kronenberg
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Flow Cytometric Analysis ◽  
Flow Cytometric ◽  
Acute Myeloid

Quantitative assessment ofBAXtranscript and flow cytometric expression in acute myeloid leukemia: A prospective study

Hematology ◽  
2014 ◽  
Vol 19 (7) ◽  
pp. 404-411
Author(s):  
Surender Kumar Sharawat ◽  
Vinod Raina ◽  
Lalit Kumar ◽  
Atul Sharma ◽  
Radhika Bakhshi ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Prospective Study ◽  
Myeloid Leukemia ◽  
Quantitative Assessment ◽  
Flow Cytometric ◽  
A Prospective Study ◽  
Acute Myeloid

Functional and Phenotypic Characterization Of Acute Myeloid Leukemia By Analysis Of Diagnostic/Relapse Paired Samples

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2595-2595
Author(s):  
Jenny M. Ho ◽  
Liran I. Shlush ◽  
Amanda Mitchell ◽  
Rene Marke ◽  
Jessica McLeod ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Disease Progression ◽  
Myeloid Leukemia ◽  
Phenotypic Characterization ◽  
Stem Cell Markers ◽  
Surface Markers ◽  
Paired Samples ◽  
Flow Cytometric ◽  
Acute Myeloid

Abstract Treatment of relapsed acute myeloid leukemia (AML) results in lower complete remission rates compared to treatment of AML at diagnosis. Immunophenotypic changes in leukemic blasts are common from diagnosis to relapse (Baer et al. Blood. 2001), suggesting that the underlying biology of AML changes with disease progression. A better understanding of the biologic properties of AML cells at different stages of disease will facilitate the development of biomarker tools and more effective therapies. We therefore studied paired diagnostic/relapse samples obtained from AML patients. Cells from 11 paired samples were transplanted into immune deficient mice (NOD.SCID IL2Rg null) over a range of cell doses. In 10 of 11 patients, a leukemic graft could be generated after transplantation of lower cell doses from the relapse sample compared to the paired diagnostic sample. By limiting dilution analysis, leukemia stem cell (LSC) frequency was higher in relapse samples (1 in 5.8×102 to 1 in 2.4×106, median 1 in 2.0×103) compared to diagnostic samples (1 in 5.0×103 to 1 in 6.1×106, median 1 in 5.5×104); the fold increase in LSC frequency ranged from 2.2 to 745 (median 8.6). Multiparameter flow cytometric analysis carried out on 13 paired diagnostic/relapse samples demonstrated an increase in 2 known stem cell markers, CD34 and CD117, from diagnosis to relapse: CD34 was gained or increased at relapse in 7/13 (54%) of paired samples, while CD117 was gained or increased at relapse in 9/13 (69%) of paired samples. We plan to take a comprehensive approach to examine the surface marker expression of paired diagnostic/relapse samples by a high throughput flow cytometric screen (HTS) of both bulk and LSC-containing AML populations to identify markers that are altered at relapse. As a first step, we have performed HTS of 373 surface markers on 10 AML patient samples, including a relapse sample from a diagnostic/relapse pair. A significant proportion of markers (155/373, 42%) were expressed on less that 5% of cells in all 10 AML samples analyzed. We will therefore focus on the remaining markers in our HTS analysis of paired samples. Surface markers that are differentially expressed from diagnosis to relapse will be further characterized in order to gain insight into disease progression and identify potential therapeutic targets. Disclosures: No relevant conflicts of interest to declare.

Prognostic Impact of Pretransplantation Minimal Residual Disease Detection for Flow Cytometric, on Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. a Single Center Experience in Colombia over 14 Years

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5411-5411
Author(s):  
Andres Armando Borda Molina ◽  
Iris Cordoba ◽  
Virginia Abello ◽  
Carmen Rosales ◽  
Rosales Manuel ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Prognostic Impact ◽  
Allogeneic Bone ◽  
Flow Cytometric ◽  
Minimal Residual ◽  
Acute Myeloid

Abstract Background: The accumulated evidence from studies of multiparameter flow cytometric MRD (MFC-MRD) assessment in AML leaves little doubt that this method of MRD detection can be used to risk stratify both younger and older patients at treatment time points. Persistence of disease or high levels of pretransplantation minimal residual disease (MRD) have been reported to predict disease relapse after Allogeneic bone marrow transplantation (BMT). The prognostic impact of MFC-MRD is strong enough to have emerged despite study differences in the MFC assays and the limitations of now outdated restricted antibody panels. Aims: To determine the value of Minimal Residual Disease (MRD) assessed by Multi-parameter Flow Cytometry (MFC) pretransplantation Allogeneic BMT, in predicting outcome in patients with acute myeloid leukemia (AML). Methods: We performed a retrospective analysis the predictive value of MRD assessment by MFC pre trasnplantation alogeneic in 119 patients (diagnosed AML treated between january 2010 and october 2014 submitted at our institution who had available MRD assessment). MRD by MFC on bone marrow specimens obtained approximately 30 days before transplantation. MRD was identified as a cell population showing deviation from normal antigen expression patters compared with normal or regenerating marrow. The detection threshold for defining pre transplantation positive MRD was >0.3%. Results - Of the 119 patients, 80 (67%) were in complete remission (CR1) , 31 (26%) CR2 and > CR2 8 (6%). Their median age was 38 years (Range, 10-64). Hyperleucocytosis in 39 (32%) and Cytogenetics was favorable risk in 32 (26%), intermediate risk in 39 (32.%), adverse risk in 35 (29%) and unknown in 13 (14%). There were a total of 44 deaths and 17 relapses; these contributed to the probability estimates for overall survival (OS) and disease free survival (DFS), stratified by MRD status and shown in figure 1. The median follow-up after BMT among survivors was 8.3 years (range, 6.9 to 9,6 years). The 7.5-years estimates of OS for MRD-positive and MRD-negative patients were 43.1% (range, 23,2% to 58,6%) and 68% (range 56% to 78.3%), respectively, and the 7,5 year estimates for DFS for MRD-positive and MRD-negative patients were 40.5% (range 21.4% to 52.6%) and 56% (range 42.5% to 65.8%). After adjustment for various covariates, age, cytogenetics risk, hyperleucocytosis, secundary AML, the hazard ratios of MRD positive versus MRD negative were 2.06 (range 1.52 to 6.24; P=0,003) for overall mortality, 3.45 ( range 2.14 to 7.32; p=0.014) for DFS. Conclusion: That detection of MRD pre transplantation define a population of patients with AML who are at higher risk for adverse outcome, even after adjusting for other factors that influence post-BMT outcome. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document